176 related articles for article (PubMed ID: 30991036)
1. Commonly used fluoroquinolones cross-react with urine drug screens for opiates, buprenorphine, and amphetamines.
Colby JM; Patel PC; Fu DY; Rutherford NJ
Clin Biochem; 2019 Jun; 68():50-54. PubMed ID: 30991036
[TBL] [Abstract][Full Text] [Related]
2. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology.
Leclercq M; Soichot M; Delhotal-Landes B; Bourgogne E; Gourlain H; Mégarbane B; Labat L
J Anal Toxicol; 2020 Mar; 44(2):200-205. PubMed ID: 31384953
[TBL] [Abstract][Full Text] [Related]
3. The analytical performance of six urine drug screens on cobas 6000 and ARCHITECT i2000 compared to LC-MS/MS gold standard.
Abou El Hassan M; Colantonio D; Likhodii S; Nassar BA
Clin Biochem; 2021 Jul; 93():99-103. PubMed ID: 33844982
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the usefulness of an oxycodone immunoassay in combination with a traditional opiate immunoassay for the screening of opiates in urine.
Gingras M; Laberge MH; Lefebvre M
J Anal Toxicol; 2010 Mar; 34(2):78-83. PubMed ID: 20223099
[TBL] [Abstract][Full Text] [Related]
5. Lack of Detection of New Amphetamine-Like Drugs Using Conventional Urinary Immunoassays.
Begeman A; Franssen EJF
Ther Drug Monit; 2018 Feb; 40(1):135-139. PubMed ID: 29194289
[TBL] [Abstract][Full Text] [Related]
6. False-positive urine opiate screening associated with fluoroquinolone use.
Zacher JL; Givone DM
Ann Pharmacother; 2004 Sep; 38(9):1525-8. PubMed ID: 15252190
[TBL] [Abstract][Full Text] [Related]
7. Cross-reactivity studies and predictive modeling of "Bath Salts" and other amphetamine-type stimulants with amphetamine screening immunoassays.
Petrie M; Lynch KL; Ekins S; Chang JS; Goetz RJ; Wu AH; Krasowski MD
Clin Toxicol (Phila); 2013 Feb; 51(2):83-91. PubMed ID: 23387345
[TBL] [Abstract][Full Text] [Related]
8. Do all screening immunoassay positive buprenorphine samples need to be confirmed?
Saleem M; Martin H; Tolya A; Coates P
Ann Clin Biochem; 2017 Nov; 54(6):707-711. PubMed ID: 28121168
[TBL] [Abstract][Full Text] [Related]
9. Effect of tramadol use on three point-of-care and one instrument-based immunoassays for urine buprenorphine.
Shaikh S; Hull MJ; Bishop KA; Griggs DA; Long WH; Nixon AL; Flood JG
J Anal Toxicol; 2008 Jun; 32(5):339-43. PubMed ID: 18544218
[TBL] [Abstract][Full Text] [Related]
10. A Retrospective Analysis of Urine Drugs of Abuse Immunoassay True Positive Rates at a National Reference Laboratory.
Johnson-Davis KL; Sadler AJ; Genzen JR
J Anal Toxicol; 2016 Mar; 40(2):97-107. PubMed ID: 26668238
[TBL] [Abstract][Full Text] [Related]
11. False-Positive Amphetamines in Urine Drug Screens: A 6-Year Review.
Pope JD; Drummer OH; Schneider HG
J Anal Toxicol; 2023 Mar; 47(3):263-270. PubMed ID: 36367744
[TBL] [Abstract][Full Text] [Related]
12. Quinolones and false-positive urine screening for opiates by immunoassay technology.
Baden LR; Horowitz G; Jacoby H; Eliopoulos GM
JAMA; 2001 Dec; 286(24):3115-9. PubMed ID: 11754677
[TBL] [Abstract][Full Text] [Related]
13. Gatifloxacin interference with opiate urine drug screen.
Straley CM; Cecil EJ; Herriman MP
Pharmacotherapy; 2006 Mar; 26(3):435-9. PubMed ID: 16503726
[TBL] [Abstract][Full Text] [Related]
14. A Novel Enzyme Immunoassay for the Detection of Buprenorphine, Norbuprenorphine and Their Glucuronides in Urine.
Schubert B; Pitterl F; Saxl B; Pavlic M
J Anal Toxicol; 2019 Jun; 43(5):364-368. PubMed ID: 30753557
[TBL] [Abstract][Full Text] [Related]
15. Interpretation and Utility of Drug of Abuse Screening Immunoassays: Insights From Laboratory Drug Testing Proficiency Surveys.
Krasowski MD; McMillin GA; Melanson SEF; Dizon A; Magnani B; Snozek CLH
Arch Pathol Lab Med; 2020 Feb; 144(2):177-184. PubMed ID: 31313960
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the Microgenics CEDIA heroin metabolite (6-AM) and the Roche Abuscreen ONLINE opiate immunoassays for the detection of heroin use in forensic urine samples.
Holler JM; Bosy TZ; Klette KL; Wiegand R; Jemionek J; Jacobs A
J Anal Toxicol; 2004 Sep; 28(6):489-93. PubMed ID: 15516301
[TBL] [Abstract][Full Text] [Related]
17. Consumption of the Sugar Substitute Stevia Leads to Cross-Reactivity of CEDIA® Buprenorphine II Immunoassay.
Plattner S; Pavlic M; Pitterl F; Schubert B
J Anal Toxicol; 2021 Nov; 45(9):1052-1057. PubMed ID: 33104778
[TBL] [Abstract][Full Text] [Related]
18. Comparison of several immunoassays used in drugs of abuse screening: Assessment against gold standard methods and calculation of measurement uncertainty.
Mina A
J Pharmacol Toxicol Methods; 2020; 101():106649. PubMed ID: 31730939
[TBL] [Abstract][Full Text] [Related]
19. False-positive buprenorphine by CEDIA in patients prescribed amisulpride or sulpiride.
Birch MA; Couchman L; Pietromartire S; Karna T; Paton C; McAllister R; Marsh A; Flanagan RJ
J Anal Toxicol; 2013 May; 37(4):233-6. PubMed ID: 23471956
[TBL] [Abstract][Full Text] [Related]
20. Accidental intoxications in toddlers: lack of cross-reactivity of vilazodone and its urinary metabolite M17 with drug of abuse screening immunoassays.
Martinez-Brokaw CD; Radke JB; Pierce JG; Ehlers A; Ekins S; Wood KE; Maakestad J; Rymer JA; Tamama K; Krasowski MD
BMC Clin Pathol; 2019; 19():2. PubMed ID: 30820187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
